AZ10419369

AZ10419369 is a small molecule partial agonist of the serotonin 5-HT1B receptor, developed primarily as a radioligand for positron emission tomography (PET) imaging. It binds with high affinity and selectivity to the 5-HT1B receptor, allowing in vivo quantification of receptor availability and occupancy in the brain. The compound has been used extensively in preclinical and clinical research to study serotonergic neurotransmission, including changes induced by pharmacological agents such as selective serotonin reuptake inhibitors (SSRIs) or serotonin releasers like fenfluramine and D-amphetamine. AZ10419369 demonstrates good brain penetration and its binding is sensitive to endogenous serotonin levels, making it valuable for assessing serotonergic function in neuropsychiatric disorders. The drug was initially developed by AstraZeneca[1][2][3][5][6].

Other names

[11c]az10419369